Physician profile
Abdullah Altayeh
NPI 1831191584
$1,713.81
in general payments reported to CMS, 2019-2025
28 companies · $312 in 2025
The $312 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $142 · 2021: $128 · 2022: $91.23 · 2023: $265 · 2024: $574 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.74 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $247.01 | 2019-2025 | Breztri, Fasenra, Tezspire |
| Glaxosmithkline, LLC. | $162.94 | 2019-2024 | Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $130.34 | 2019-2025 | Dupixent |
| Philips North America LLC | $127.18 | 2024-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Janssen Pharmaceuticals, INC | $113.63 | 2024 | Opsumit, Uptravi |
| United Therapeutics Corporation | $100.00 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $78.99 | 2024 | Opsumit, Uptravi |
| Livanova USA, INC. | $72.32 | 2019 | |
| Intuitive Surgical, INC. | $68.70 | 2023 | Da Vinci Surgical System |
| Sunovion Pharmaceuticals INC. | $58.62 | 2019 | |
| Insmed, INC. | $56.43 | 2022-2025 | Arikayce |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.48 | 2021-2024 | Ofev |
| Abiomed | $49.67 | 2024 | Impella |
| Genzyme Corporation | $40.82 | 2021-2022 | |
| Viatris Specialty LLC | $37.50 | 2025 | Yupelri |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $36.64 | 2021-2024 | Yupelri |
| Verona Pharma, INC. | $33.85 | 2025 | Ohtuvayre |
| Inogen, INC. | $29.80 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Novartis Pharmaceuticals Corporation | $26.50 | 2025 | |
| Tactile Systems Technology INC | $24.70 | 2025 | Nimbl, Flexitouch Plus |
| Bayer Healthcare Pharmaceuticals INC. | $24.40 | 2023 | |
| Novo Nordisk INC | $23.25 | 2024 | Wegovy |
| Amgen INC. | $23.19 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.56 | 2021 | |
| Mallinckrodt Hospital Products INC. | $21.19 | 2024 | Acthar |
| Grifols USA, LLC | $19.18 | 2025 | Prolastin-C Liquid |
| Vifor Pharma, INC. | $18.24 | 2024 | Zemaira |
| Electromed, INC. | $14.68 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Altayeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.